Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.67 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488332 | 0.87 | MAPK14 (0.59) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL6275051 | 0.85 | MAPK14 (0.54) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL3374385 | 0.79 | EPHX2 (0.56) | — | |
| SCHEMBL13702344 | 0.78 | AOC3 (0.54) | — | |
| SCHEMBL6655486 | 0.78 | S1PR4 (0.67) | MAPK14 | |
| SCHEMBL13146376 | 0.78 | MAPK14 (0.79) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL5633482 | 0.76 | MAPK14 (0.77) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL6658772 | 0.76 | MAPK14 (0.74) | MAPK14CYP2C9MAPK11 | |
| SCHEMBL6748200 | 0.76 | MAPK14 (0.77) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL4151138 | 0.76 | NR1H4 (0.61) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435933-A1 | 5'-CARBAMOYL-2'-METHYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032970-A1 | 5'-CARBAMOYL-2'-METHYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |